Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

NCT00189917 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic
Hay Fever

Interventions

BIOLOGICAL: IMVAMUNE (MVA-BN)

Sponsor

Bavarian Nordic

Collaborators

[object Object]